Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study

AFIB-ICU Collaborators, Mik Wetterslev, Morten Hylander Møller, Anders Granholm, Christian Hassager, Nicolai Haase, Theis Lange, Sheila N. Myatra, Johanna Hästbacka, Yaseen M. Arabi, Jiawei Shen, Maria Cronhjort, Elin Lindqvist, Anders Aneman, Paul J. Young, Wojciech Szczeklik, Martin Siegemund, Thijs Koster, Tayyba Naz Aslam, Morten H. BestleMia S. Girkov, Kushal Kalvit, Rakesh Mohanty, Joanne Mascarenhas, Manoranjan Pattnaik, Sara Vergis, Sai Praveen Haranath, Mitul Shah, Ziyokov Joshi, Erika Wilkman, Matti Reinikainen, Pasi Lehto, Ville Jalkanen, Anni Pulkkinen, Youzhong An, Guoxing Wang, Lei Huang, Bin Huang, Wei Liu, Hengbo Gao, Lin Dou, Shuangling Li, Wanchun Yang, Emily Tegnell, Agnes Knight, Miroslaw Czuczwar, Tomasz Czarnik, Anders Perner

Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

9 Sitaatiot (Scopus)

Abstrakti

OBJECTIVES: To assess the incidence, risk factors, and outcomes of atrial fibrillation (AF) in the ICU and to describe current practice in the management of AF. DESIGN: Multicenter, prospective, inception cohort study. SETTING: Forty-four ICUs in 12 countries in four geographical regions. SUBJECTS: Adult, acutely admitted ICU patients without a history of persistent/permanent AF or recent cardiac surgery were enrolled; inception periods were from October 2020 to June 2021.None. MEASUREMENTS AND MAIN RESULTS: We included 1,423 ICU patients and analyzed 1,415 (99.4%), among whom 221 patients had 539 episodes of AF. Most (59%) episodes were diagnosed with continuous electrocardiogram monitoring. The incidence of AF was 15.6% (95% CI, 13.8-17.6), of which newly developed AF was 13.3% (11.5-15.1). A history of arterial hypertension, paroxysmal AF, sepsis, or high disease severity at ICU admission was associated with AF. Used interventions to manage AF were fluid bolus 19% (95% CI 16-23), magnesium 16% (13-20), potassium 15% (12-19), amiodarone 51% (47-55), beta-1 selective blockers 34% (30-38), calcium channel blockers 4% (2-6), digoxin 16% (12-19), and direct current cardioversion in 4% (2-6). Patients with AF had more ischemic, thromboembolic (13.6% vs 7.9%), and severe bleeding events (5.9% vs 2.1%), and higher mortality (41.2% vs 25.2%) than those without AF. The adjusted cause-specific hazard ratio for 90-day mortality by AF was 1.38 (95% CI, 0.95-1.99). CONCLUSIONS: In ICU patients, AF occurred in one of six and was associated with different conditions. AF was associated with worse outcomes while not statistically significantly associated with 90-day mortality in the adjusted analyses. We observed variations in the diagnostic and management strategies for AF.

AlkuperäiskieliEnglanti
Sivut1124-1137
Sivumäärä14
JulkaisuCritical Care Medicine
Vuosikerta51
Numero9
DOI - pysyväislinkit
TilaJulkaistu - syysk. 2023
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

  • Jufo-taso 2

!!ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Sormenjälki

Sukella tutkimusaiheisiin 'Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä